| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca82d85ba526a9d85bc53f9c7a5be440 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-102
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-907
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y305-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 |
| filingDate |
2019-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fb3521388df3b2777f39f9949376a93
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_201bb78e16c5db3d317db65488d344dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81614ac6707dddf9c502c0b4868de9f2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_619e1ed8f13b81b6bc2f218247c69c6c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df68f90cd2fc68d7650ddc831600a844
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_089847b8424e9781c2f87078426eb43e |
| publicationDate |
2021-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021163913-A1 |
| titleOfInvention |
Fusion proteins for base editing |
| abstract |
Provided are fusion proteins that include an apolipoprotein B mRNA editing enzyme catalytic subunit 3A (APOBEC3A) and a clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) protein, optionally further with uracil glycosylase inhibitor (UGI). Such a fusion protein is able to conduct base editing in DNA by deaminating cytosine to uracil, even when the cytosine is in a GpC context or is methylated. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114045302-A |
| priorityDate |
2018-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |